Table 2.
Patient’s therapy prior to surgery.
| Therapy Prior to Surgery | NDM (n = 17) |
T2DM (n = 21) |
|---|---|---|
| ACE inhibitors (n, %) | 7 (41.2%) | 16 (76.2%) |
| β blockers (n, %) | 9 (52.9%) | 16 (76.2%) |
| CCBs (n, %) | 2 (11.8%) | 6 (28.6%) |
| Diuretics (n, %) | 4 (23.6%) | 6 (28.6%) |
| Statins (n, %) | 8 (47.1%) | 7 (33.3%) |
| Antiplatelet drugs (n, %) | 12 (70.6%) | 11 (52.4%) |
| Vasodilators (n, %) | 5 (29.4%) | 11 (52.4%) |
| Anticoagulants (n, %) | 2 (11.8%) | 5 (23.8%) |
Antidiabetics
|
0 0 |
14 (66.7%) 9 (42.9%) |
NDM—non diabetes mellitus patients; T2DM—type-2 diabetes mellitus patients; n—number of patients; CCB—calcium channels blockers.